Free tool
FAERS Monitor: Voltaren Arthritis Pain
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022122 or its brand name (Voltaren Arthritis Pain, Diclofenac Sodium). Reports on generic versions are filed under their own applications.
Reports
101,833
Serious
50,966
50% of reports
Hospitalization
24,333
Death reported
9,959
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective23,949
- product use in unapproved indication11,995
- off label use10,311
- pain10,013
- fatigue9,014
- product use issue8,022
- rash7,842
- rheumatoid arthritis7,286
- product administered at inappropriate site7,061
- abdominal discomfort6,878
- arthralgia6,813
- drug effective for unapproved indication6,788
- alopecia6,322
- systemic lupus erythematosus6,268
- joint swelling6,248
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1,074 |
| 2005 | 1,133 |
| 2006 | 1,113 |
| 2007 | 1,326 |
| 2008 | 1,507 |
| 2009 | 1,550 |
| 2010 | 1,878 |
| 2011 | 2,386 |
| 2012 | 2,241 |
| 2013 | 1,114 |
| 2014 | 1,643 |
| 2015 | 3,496 |
| 2016 | 4,866 |
| 2017 | 3,849 |
| 2018 | 4,046 |
| 2019 | 3,933 |
| 2020 | 10,738 |
| 2021 | 15,424 |
| 2022 | 8,874 |
| 2023 | 9,932 |
| 2024 | 9,046 |
| 2025 | 6,972 |
| 2026 | 3,685 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,952,326 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product administered at inappropriate siteSignal | 7,061 | 128.7 | 125.0 | 550,906 |
| drug effective for unapproved indicationSignal | 6,788 | 62.0 | 60.4 | 313,372 |
| systemic lupus erythematosusSignal | 6,268 | 44.1 | 42.9 | 217,644 |
| rheumatoid arthritisSignal | 7,286 | 14.1 | 13.8 | 83,395 |
| joint swellingSignal | 6,248 | 11.2 | 10.9 | 55,460 |
| product use in unapproved indicationSignal | 11,995 | 10.5 | 10.3 | 98,742 |
| product use issueSignal | 8,022 | 9.2 | 9.0 | 56,355 |
| abdominal discomfortSignal | 6,878 | 8.8 | 8.6 | 45,882 |
| alopeciaSignal | 6,322 | 6.8 | 6.7 | 30,771 |
| drug ineffectiveSignal | 23,949 | 3.8 | 3.8 | 51,851 |
| rashSignal | 7,842 | 3.8 | 3.7 | 15,970 |
| arthralgiaSignal | 6,813 | 3.4 | 3.3 | 11,730 |
| painSignal | 10,013 | 3.4 | 3.3 | 17,242 |
| off label useSignal | 10,311 | 2.4 | 2.4 | 9,116 |
| fatigueSignal | 9,014 | 2.4 | 2.4 | 7,613 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.